OHSU
Categories | Inventors

Humanized T cell hybridoma specific for myelin oligodendrocyte glycoprotein 35-55 peptide

 

OHSU # 0824

Technology Overview
This hybridoma offers a laboratory tool to identify, screen, and characterize T-cell immune modulatory agents for use in treating patients with immune disorders including multiple sclerosis.

This technology describes a T cell hybridoma specific for, and reactive to, human myelin oligodendrocyte glycoprotein (MOG)-35-55. The T-cell hybridoma is positive for D3(+) and CD4(+) cells and negative for CD8(-) cells, expresses TCR BV8/AV11 and AV17 genes, and produces IL-2, IFN-y and TNF-a Th1 cytokines upon concanavalin A or MOG peptide stimulation. The MOG-35-55 peptide-specific T-cell hybridoma is a novel, humanized T-cell reagent can induce experimental autoimmune encephalomyelitis (EAE) in mice and can be recognized by T cells from patients with multiple sclerosis. It is useful for standardized biological screening as well as activation pathways induced by MOG-35-55 peptide associated with T-cell ligands  or presented by antigen presenting cell (APC).

Market Overview

- Multiple sclerosis is a debilitating neurological autoimmune disease with a higher incidence in women

- More than 400,000 Americans affected

- About 2.1 million people are affected worldwide

- MS patients develop clinical signs at about age 30, and require increasing care as their disease progresses and their   

   productivity decreases over the duration of their normal lifespan

- There is no cure for MS. Currently, treatments include disease modifying agents that attempt to reduce disease activity

   and progression, symptom treatment, and methods to improve life functions

Licensing Opportunity

The technology is available for licensing on a non-exclusive basis for internal use.  

Inventors:

Patents:

Patents Filed

Categories:

For more information, contact:

Michele Gunness
Senior Technology Development Manager
503-494-4184